Ghent University Academic Bibliography

Advanced

Noradrenaline (norepinephrine) and depression: role in aetiology and therapeutic implications

Myriam Van Moffaert and Michel Dierick UGent (1999) CNS DRUGS. 12(4). p.293-305
abstract
In the pharmacological treatment of depression the focus has recently shifted from serotonin (5-hydroxytryptamine; 5-HT) to noradrenaline (norepinephrine), with the advent of new antidepressants such as noradrenaline reuptake inhibitors, noradrenergic and selective serotonergic antidepressants, and serotonin/noradrenaline reuptake inhibitors. It has been suggested that noradrenergic compounds may prove to have beneficial activity in those depressions that are characterised by a 'noradrenergic deficiency syndrome', which is clinically manifested through emotional withdrawal, psychomotor retardation, as well as concentration and memory deficits. The role of noradrenergic mechanisms in the aetiology of depression has been assumed since the catecholamine hypothesis, based on the inhibitory action of tricyclic antidepressants and monoamine oxidase inhibitors on noradrenaline uptake, was formulated. In this article, the aetiological significance of noradrenaline in depression is discussed with regard to the anatomical basis of the noradrenergic system (the locus caeruleus), noradrenaline metabolites, noradrenergic receptors, some aspects of thyroid function and the hypothalamic-pituitary-adrenal axis. The efficacy and tolerability profiles of new antidepressant compounds reboxetine, milnacipran, mirtazapine and venlafaxine are discussed in view of their noradrenergic activity.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
CATECHOLAMINE DEPLETION, ANTIDEPRESSANT-INDUCED REMISSION, MAJOR DEPRESSION, NEUROBIOLOGY, MIRTAZAPINE, MECHANISM
journal title
CNS DRUGS
CNS Drugs
volume
12
issue
4
pages
293 - 305
Web of Science type
Review
Web of Science id
000083316400004
ISSN
1172-7047
DOI
10.2165/00023210-199912040-00004
language
English
UGent publication?
yes
classification
A1
id
175055
handle
http://hdl.handle.net/1854/LU-175055
date created
2004-01-14 13:40:00
date last changed
2016-12-19 15:38:09
@article{175055,
  abstract     = {In the pharmacological treatment of depression the focus has recently shifted from serotonin (5-hydroxytryptamine; 5-HT) to noradrenaline (norepinephrine), with the advent of new antidepressants such as noradrenaline reuptake inhibitors, noradrenergic and selective serotonergic antidepressants, and serotonin/noradrenaline reuptake inhibitors. It has been suggested that noradrenergic compounds may prove to have beneficial activity in those depressions that are characterised by a 'noradrenergic deficiency syndrome', which is clinically manifested through emotional withdrawal, psychomotor retardation, as well as concentration and memory deficits. 
The role of noradrenergic mechanisms in the aetiology of depression has been assumed since the catecholamine hypothesis, based on the inhibitory action of tricyclic antidepressants and monoamine oxidase inhibitors on noradrenaline uptake, was formulated. In this article, the aetiological significance of noradrenaline in depression is discussed with regard to the anatomical basis of the noradrenergic system (the locus caeruleus), noradrenaline metabolites, noradrenergic receptors, some aspects of thyroid function and the hypothalamic-pituitary-adrenal axis. 
The efficacy and tolerability profiles of new antidepressant compounds reboxetine, milnacipran, mirtazapine and venlafaxine are discussed in view of their noradrenergic activity.},
  author       = {Van Moffaert, Myriam and Dierick, Michel},
  issn         = {1172-7047},
  journal      = {CNS DRUGS},
  keyword      = {CATECHOLAMINE DEPLETION,ANTIDEPRESSANT-INDUCED REMISSION,MAJOR DEPRESSION,NEUROBIOLOGY,MIRTAZAPINE,MECHANISM},
  language     = {eng},
  number       = {4},
  pages        = {293--305},
  title        = {Noradrenaline (norepinephrine) and depression: role in aetiology and therapeutic implications},
  url          = {http://dx.doi.org/10.2165/00023210-199912040-00004},
  volume       = {12},
  year         = {1999},
}

Chicago
Van Moffaert, Myriam, and Michel Dierick. 1999. “Noradrenaline (norepinephrine) and Depression: Role in Aetiology and Therapeutic Implications.” Cns Drugs 12 (4): 293–305.
APA
Van Moffaert, Myriam, & Dierick, M. (1999). Noradrenaline (norepinephrine) and depression: role in aetiology and therapeutic implications. CNS DRUGS, 12(4), 293–305.
Vancouver
1.
Van Moffaert M, Dierick M. Noradrenaline (norepinephrine) and depression: role in aetiology and therapeutic implications. CNS DRUGS. 1999;12(4):293–305.
MLA
Van Moffaert, Myriam, and Michel Dierick. “Noradrenaline (norepinephrine) and Depression: Role in Aetiology and Therapeutic Implications.” CNS DRUGS 12.4 (1999): 293–305. Print.